IPOs With Potential...
Health Care: Drugs
Onyx Pharmaceuticals Inc. (ONXX: NASDAQ)
$42.45 -0.09 | -0.21%
02/09/12 - 04:00 PM ET
638.96K / 1.46M
Vol / Avg. Vol:42.53 / 42.54
Open / Prev. Close:41.66 - 42.68
Today's Range:27.17 - 46.07
52 Wk Range:-3.21%
Performance YTD:TheStreet Rating:
Portfolios with ONXX
- Portfolio NameUser Type
- Userjet189 Portfolio 1
- ContributorStocks Rising On Unusal Vol...
- ContributorCancer Drug Stocks to Trade...
- ProBridger Management
- UserPortfolio 1
- ContributorBarclays' 30 Best Stock Pic...
- UserArticStryker's Portfolio
- Usermulligans13
- ProDuquesne Capital
- UserASCO 2010 Part 2
Latest ONXX Headlines from TheStreet
- Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger 01.20.12 | 05:01 am
- Onyx Colon Cancer Drug Juggles Survival Benefit With Serious Side Effects 01.18.12 | 09:01 am
- Onyx Colon Cancer Drug Juggles Survival Benefit With Serious Side Effects 01.17.12 | 07:01 pm
- Biotech Lessons Learned From JPM 2012 01.13.12 | 06:01 am
- J.P. Morgan Biotech Confab Live Chat 01.09.12 | 07:01 pm
- The Next Big Thing In Biotech: 2012 Outlook
01.06.12 | 05:01 am - Aveo Beats Onyx in Study of Dueling Kidney Cancer Drugs 01.03.12 | 10:01 am
- Watch These Biotech Trends In 2012 12.19.11 | 06:12 am
- Onyx Trips, Ariad and Pharmacyclics Shine at Blood Cancer Meeting 12.12.11 | 07:12 am
- Biotech Stock Mailbag: Affymax 12.02.11 | 06:12 am
Press Releases for ONXX
- Onyx Pharmaceuticals Announces Fourth Quarter And Full Year 2011 Financial Results Teleconference And Webcast - PR Newswire 02.09.12 | 04:02 pm
- Onyx Pharmaceuticals To Present At The 30th Annual J.P. Morgan Healthcare Conference - PR Newswire 01.03.12 | 04:01 pm
- Multiple Myeloma Research Foundation (MMRF) And Onyx Pharmaceuticals Announce Multi-Year Collaboration To Accelerate Personalized Medicine Approaches For Multiple Myeloma - PR Newswire 12.14.11 | 09:12 am
- Onyx Pharmaceuticals Presents Carfilzomib Data At 53rd American Society Of Hematology Annual Meeting - PR Newswire 12.12.11 | 09:12 pm
- Onyx Pharmaceuticals Announces FDA Standard Review Designation Of Carfilzomib New Drug Application For The Treatment Of Relapsed And Refractory Multiple Myeloma - PR Newswire 12.11.11 | 08:12 pm
- Onyx Pharmaceuticals Provides Update On Carfilzomib At 53rd American Society Of Hematology Annual Meeting - PR Newswire 12.10.11 | 09:12 pm
- Onyx Pharmaceuticals To Host A Teleconference To Reprise Key Data From The American Society Of Hematology Meeting - PR Newswire 12.06.11 | 04:12 pm
- Onyx Pharmaceuticals Announces FDA Acceptance Of New Drug Application For Carfilzomib For The Treatment Of Relapsed And Refractory Multiple Myeloma - PR Newswire 11.29.11 | 08:11 am
- Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib At 53rd American Society Of Hematology Annual Meeting - PR Newswire 11.07.11 | 04:11 pm
- Onyx Pharmaceuticals To Present At Two Upcoming Healthcare Conferences - PR Newswire 11.03.11 | 04:11 pm
Partner Headlines for ONXX
- 16 Stocks Trading Near Highs With Bullish Short Trends - Seeking Alpha 01.09.12 | 08:01 am
- Pipeline Setback at Bristol-Myers - Analyst Blog - Zacks 12.23.11 | 10:12 am
- Positive Data on Novartis' Afinitor - Analyst Blog - Zacks 12.12.11 | 10:12 am
- UPDATE: Goldman Sachs Reiterates Buy, Lowers PT $45 on Onyx Pharmaceuticals - Benzinga 12.12.11 | 09:12 am
- Jefferies Maintains Buy on Onyx Pharma After FDA Acceptance of NDA Filing - Benzinga 11.29.11 | 09:11 am
- Celgene's Revlimid Cleared in Sweden - Analyst Blog - Zacks 11.23.11 | 04:11 pm
- Biotech Investing Lessons Learned: Diversify, Be Patient - Seeking Alpha 10.27.11 | 09:10 am
- BMS Drug Deemed Too Costly: Weekly Round-Up Of Biotech Failures And Mishaps - Seeking Alpha 10.16.11 | 08:10 am
- ONYX PHARMA INC (ONXX) - Profit Tracks - Zacks 08.24.11 | 01:08 am
- Novartis' Afinitor Impresses Again - Analyst Blog - Zacks 07.07.11 | 10:07 am
